SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chiroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: UPAL who wrote (21)2/15/1998 10:43:00 AM
From: James Reynolds  Read Replies (1) of 69
 
UPAL,

A decision on European approval for Chiroscience's Chirocaine should come mid/late 98. Obviously, approval will be a big boost and the share price should rise to reflect this. Prior to this, maybe in the next 3 mths, a marketing partner for Chirocaine should be announced - according to the NY Times possible partners include Abbot, Glaxo and Zeneca.

A decision on European approvals for Cortec's Macritonin should come by late 98. Macritonin (an oral calcitonin product) has thus far shown equivalent efficacy to Merck's Nasal Calcitonin in ongoing PIII trials and a marketing partner is expected to be announced by mid 98. Cortecs has several other products on which news is expected during 98 including its Pseudostat oral vaccine, its oral insulin product, as well as the launch of its new diabetes and osteoporosis monitoring kits.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News